ArticleCancer immunology, immunotherapy : CII2023

Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.

Matteo Santoni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.